Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 3/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | CCR9 | P51686 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20062894 | 0.89 | CA12 (0.35) | CCR9HSD11B1ALDH1A1HTTMEN1 | |
| SCHEMBL18905690 | 0.84 | KIF11 (0.40) | PDPK1KIF11ALDH1A1TSHRKMT2A | |
| SCHEMBL20062896 | 0.79 | ELANE (0.33) | CCR9HPGD | |
| SCHEMBL20062902 | 0.77 | MEN1 (0.31) | ALDH1A1MEN1KMT2A | |
| SCHEMBL19343014 | 0.75 | HSP90AA1 (0.39) | KIF11ALDH1A1HPGDKMT2ASMN1; SMN2 | |
| SCHEMBL18905679 | 0.73 | CA9 (0.39) | KIF11ALDH1A1MEN1HPGDTSHR | |
| SCHEMBL18905684 | 0.73 | CA9 (0.39) | KIF11ALDH1A1MEN1HPGDTSHR | |
| SCHEMBL12173602 | 0.73 | KIF11 (0.53) | KIF11ALDH1A1TSHRKMT2ACA12 | |
| SCHEMBL14062425 | 0.73 | KIF11 (0.53) | KIF11ALDH1A1TSHRKMT2ACA12 | |
| SCHEMBL20062898 | 0.73 | CHRNB2 (0.40) | MEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10541260-B2 | Organic photoelectric conversion element, optical area sensor, imaging device, and imaging apparatus | CANON KABUSHIKI KAISHA (JP) | 2020-01-21 | — | — | US | disclosed |
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | CANON KABUSHIKI KAISHA (JP) | 2019-01-29 | — | — | US | disclosed |
| US-20180108691-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2018-04-19 | — | — | US | disclosed |
| US-20180108691-A1 | ORGANIC PHOTOELECTRIC CONVERSION ELEMENT, OPTICAL AREA SENSOR, IMAGING DEVICE, AND IMAGING APPARATUS | CANON KABUSHIKI KAISHA (JP) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10193084-B2 | 2,2′-bibenzo[D]imidazolidene compound having heteromonocyclic groups at the 1-, 1′-, 3- and 3′- positions, and organic light-emitting element and display device containing the same | BRD1, DRD1, NR2E3 | PDPK1 3236/4885KIF11 3941/4885FLT3 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.